% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Hansen:163683,
author = {Hansen, Niels and Stöcker, Winfried and Wiltfang, Jens and
Bartels, Claudia and Rentzsch, Kristin and Bouter, Caroline},
title = {{C}ase {R}eport: {S}emantic {V}ariant of {P}rimary
{P}rogressive {A}phasia {A}ssociated {W}ith {A}nti-{G}lial
{F}ibrillary {A}cid {P}rotein {A}utoantibodies.},
journal = {Frontiers in immunology},
volume = {12},
issn = {1664-3224},
address = {Lausanne},
publisher = {Frontiers Media},
reportid = {DZNE-2022-00429},
pages = {760021},
year = {2022},
abstract = {Frontotemporal lobar degeneration is a heterogeneous
disorder entailing a semantic variant of primary progressive
aphasia (svPPA). A subtype of frontotemporal dementia
associated with glutamate receptor subunit 3 (GluA3)
antibody of the
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPAR) was recently identified. Here, we describe
the novelty of a svPPA associated with anti-glial fibrillary
acid protein (GFAP) antibodies.To diagnose this 68-year-old
woman we conducted a clinical examination,
neuropsychological testing, CSF analysis, MRI and
18F-fluorodeoxyglucose (18F-FDG) Positron Emission
Tomography (PET)/computed tomography (CT) imaging.The
clinical phenotype corresponds to a svPPA based on impaired
confrontation naming and single-word comprehension. In
addition, we observed spared speech production, impaired
object knowledge, and surface dyslexia - further supporting
the diagnosis of svPPA. Additional characteristic imaging
features such as anterior temporal hypometabolism in 18F-FDG
PET/CT confirmed patient's svPPA diagnosis. CSF analysis
revealed signs of axonal degeneration, as both tau and
phosphorylated tau proteins exceeded normal levels. Her
serum showed anti-GFAP autoantibodies.We diagnosed a svPPA
in this patient and report an association between serum
anti-GFAP antibodies and svPPA never reported in the
literature so far, thereby expanding the clinical spectrum
of svPPA and anti-GFAP-antibody related disease. Further
research is needed to elucidate the underlying
immunopathology of this disease entity to ultimately improve
treatment.},
keywords = {Aged / Aphasia, Primary Progressive: immunology /
Autoantibodies: immunology / Autoantigens: immunology /
Female / Glial Fibrillary Acidic Protein: immunology /
Humans / anti-GFAP antibody (Other) / autoimmunity (Other) /
frontotemporal lobar degeneration (FTLD) (Other) /
immunotherapy (Other) / semantic variant of primary
progressive aphasia (svPPA) (Other) / Autoantibodies (NLM
Chemicals) / Autoantigens (NLM Chemicals) / GFAP protein,
human (NLM Chemicals) / Glial Fibrillary Acidic Protein (NLM
Chemicals) / anti-GFAP autoantibodies (NLM Chemicals)},
cin = {AG Wiltfang},
ddc = {610},
cid = {I:(DE-2719)1410006},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:35046935},
pmc = {pmc:PMC8761624},
doi = {10.3389/fimmu.2021.760021},
url = {https://pub.dzne.de/record/163683},
}